Efficacy and safety of anti-obesity drugs in children and adolescents: Systematic review and meta-analysis: Obesity management

Obesity Reviews

Volumn 11, Issue 8, 2010, Pages 593-602

  Viner, R M ^a   Hsia, Y ^b   Tomsic, T ^b   Wong, I C K ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anti obesity drug; child; pharmacotherapy; systematic review

Indexed keywords

ANTIOBESITY AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; ANOREXIGENIC AGENT; CYCLOBUTANE DERIVATIVE; LACTONE;

ABDOMINAL PAIN; ADOLESCENCE; BODY MASS; CARDIOVASCULAR RISK; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; DATA ANALYSIS; DEFECATION URGENCY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EFFECT SIZE; EMBASE; FECES INCONTINENCE; FLATULENCE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MEDLINE; META ANALYSIS; OBESITY; OILY SPOTTING; PEDIATRICS; PREVALENCE; QUALITY CONTROL; REVIEW; SIDE EFFECT; STEATORRHEA; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; XEROSTOMIA; ADOLESCENT; COGNITIVE THERAPY; DRUG EFFECTS; FEMALE; MALE; MULTIMODALITY CANCER THERAPY; PRODUCT SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; WEIGHT REDUCTION;

ADOLESCENT; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BODY MASS INDEX; CHILD; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; CONSUMER PRODUCT SAFETY; CYCLOBUTANES; FEMALE; HUMANS; LACTONES; MALE; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 77954748599     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2009.00651.x     Document Type: Review

References (35)

1. Lobstein T, Leach RJ. Tackling Obesities: Future Choices - International Comparisons of Obesity Trends, Determinants and Responses - Evidence Review - 2 Children. Government Office for Science
2. Reilly JJ, Methven E, McDowell ZC, Hacking B, Alexander D, Stewart L, Kelnar CJ. Health consequences of obesity. Arch Dis Child 2003 88 : 748 752.
3. Baker JL, Olsen LW, Sorensen TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med 2007 357 : 2329 2337.
4. Freemark M. Pharmacotherapy of childhood obesity: an evidence-based, conceptual approach. Diabetes Care 2007 30 : 395 402.
5. August GP, Caprio S, Fennoy I, Freemark M, Kaufman FR, Lustig RH, Silverstein JH, Speiser PW, Styne DM, Montori VM. Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. J Clin Endocrinol Metab 2008 93 : 4576 4599.
6. National Institute for Health and Clinical Excellence. Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. NICE Clinical Guideline 43; December 2006. 2006.
7. Hsia YH, Neubert AC, Viner RM, Wong ICK. Dramatic rise in anti-obesity drug prescribing in children and adolescents: a population-based study in the UK. Pharmacoepidemiol Drug Saf 2008 17 : S318.
8. European Medicines Agency (EMEA). Press Release: European Medicines Agency Recommends First Switch from Prescription-Only to Non-Prescription for a Centrally Authorised Medicine. 23-10-2008. European Medicines Agency (EMEA)
9. McGovern L, Johnson JN, Paulo R, Hettinger A, Singhal V, Kamath C, Erwin PJ, Montori VM. Treatment of pediatric obesity. A systematic review and meta-analysis of randomized trials. J Clin Endocrinol Metab 2008 98 : 4600 4605.
10. Oude Luttikhuis H, Baur L, Jansen H, Shrewsbury VA, O'Malley C, Stolk RP, Summerbell CD. Interventions for treating obesity in children. Cochrane Database Syst Rev 2009 1 CD001872.
11. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions V 5.0.1. 2008. [WWW document]. URL http://www.cochrane-handbook. org (accessed February 2008).
12. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994 309 : 1286 1291.
13. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000 320 : 1240 1243.
14. Egger M, Smith GD, Altman D. Systematic Reviews in Health Care: Meta-Analysis in Context. BMJ Books
15. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999 354 : 1896 1900.
16. Cole TJ, Faith MS, Pietrobelli A, Heo M. What is the best measure of adiposity change in growing children: BMI, BMI %, BMI z-score or BMI centile? Eur J Clin Nutr 2005 59 : 419 425.
17. Reisler G, Tauber T, Afriat R, Bortnik O, Goldman M. Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity. Isr Med Assoc J 2006 8 : 30 32.
18. Violante-Ortiz R, Del-Rio-Navarro BE, Lara-Esqueda A, Perez P, Fanghanel G, Madero A, Berber A. Use of sibutramine in obese Hispanic adolescents. Adv Ther 2005 22 : 642 649.
19. Van Mil EG, Westerterp KR, Kester AD, Delemarre-van de Waal HA, Gerver WJ, Saris WH. The effect of sibutramine on energy expenditure and body composition in obese adolescents. J Clin Endocrinol Metab 2007 92 : 1409 1414.
20. Danielsson P, Janson A, Norgren S, Marcus C. Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. J Clin Endocrinol Metab 2007 92 : 4101 4106.
21. McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002 10 : 642 650.
22. Norgren S, Danielsson P, Jurold R, Lotborn M, Marcus C. Orlistat treatment in obese prepubertal children: a pilot study. Acta Paediatr 2003 92 : 666 670.
23. McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Frazer TE, Van HS, Yanovski JA. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab 2004 17 : 307 319.
24. Ozkan B, Bereket A, Turan S, Keskin S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004 163 : 738 741.
25. Godoy-Matos A, Carraro L, Vieira A, Oliveira J, Guedes EP, Mattos L, Rangel C, Moreira RO, Coutinho W, Appolinario JC. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab 2005 90 : 1460 1465.
26. Garcia-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvarez LM. Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2006 28 : 770 782.
27. Berkowitz RI, Fujioka K, Daniels SR, Hoppin AG, Owen S, Perry AC, Sothern MS, Renz CL, Pirner MA, Walch JK, Jasinsky O, Hewkin AC, Blakesley VA. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006 145 : 81 90.
28. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003 289 : 1805 1812.
29. Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch Dis Child 1995 73 : 25 29.
30. Centers for Disease Control. CDC 2000 Charts: United States. 2009. [WWW document]. URL http://www.cdc.gov/GrowthCharts/ (accessed October 2009).
31. McCarthy HD, Ellis SM, Cole TJ. Central overweight and obesity in British youth aged 11-16 years: cross sectional surveys of waist circumference. BMJ 2003 326 : 624.
32. Viner RM, Bryant-Waugh R, Nicholls D, Christie D. Aim should be weight maintenance not loss. BMJ 2000 320 : 1401.
33. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007 335 : 1194 1199.
34. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005 293 : 2873 2883.
35. Maahs D, de Serna DG, Kolotkin RL, Ralston S, Sandate J, Qualls C, Schade DS. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 2006 12 : 18 28.